Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: J Biomol Struct Dyn. 2022 Dec 16;41(19):9808–9827. doi: 10.1080/07391102.2022.2153269

Figure 5: Protein Array Analysis of a In Vivo Xenograft Tumor Model of EGFR TKI Resistance.

Figure 5:

Mice were inoculated with H1650 human lung cancer cells. Mice began treatment when tumors became palpable (2–3mm diameter) and were treated every day with vehicle control or 50mg/kg lapatinib. Protein was collected from H1650 tumors (N=5), samples were pooled equally, and the PhosphoExplorer antibody array was performed (Full Moon Biosystems). RFU for all significantly differently expressed proteins is shown (N=2). A 2-Way ANOVA and Bonferroni post hoc tests were used to determine significance. * = p<0.05, ** = p<0.01, *** = P<0.001.